Key Takeaways
- • KMM Group, a Hatboro, Pennsylvania-based precision contract manufacturer for the medical device industry, completed a growth equity investment from RS2 Healthcare Partners, a Boston-based private equity firm, as of July 27, 2026.
- • J. Mark King was appointed President and Chief Executive Officer, bringing 30+ years of medical device industry experience and prior tenure as CEO of Tegra Medical, another RS2 portfolio company, signaling operational continuity and strategic alignment.
- • Co-founders John Shegda and Eric Wilhelm transitioned to Chief Technology Officer and Executive Vice President of Business Transformation & Organizational Capability, respectively, positioning the company for expansion while maintaining customer and employee continuity.
- • The investment will fund expansion of KMM's manufacturing capabilities and strengthen its market position as a contract manufacturer for medtech and other highly demanding, precision-tolerance markets.
- • Middle Branch Partners provided advisory services to KMM Group during the transaction; Choate provided legal representation to RS2 Healthcare Partners.
Summary
KMM Group, a vertically integrated precision contract manufacturer headquartered in Hatboro, Pennsylvania, has completed a growth equity investment from RS2 Healthcare Partners, a Boston-based private equity firm, according to an announcement dated July 27, 2026. The transaction represents a significant capital infusion intended to support the company's manufacturing expansion and market positioning within the medical device sector and other highly regulated, precision-dependent industries.
The investment is accompanied by a leadership restructuring designed to balance growth acceleration with operational continuity. J. Mark King has been appointed President and Chief Executive Officer. King brings extensive industry credentials, including over 30 years in the medical device sector and prior service as President and CEO of Tegra Medical, a contract manufacturer that was itself a portfolio company of RS2 Healthcare Partners. His familiarity with RS2's operational framework and investment strategy positions him to execute growth initiatives while maintaining alignment with the private equity sponsor's value-creation thesis.
Co-founder John Shegda has assumed the role of Chief Technology Officer, with responsibility for engineering and technology strategy, while co-founder Eric Wilhelm has been named Executive Vice President of Business Transformation & Organizational Capability, overseeing operational excellence and scalable growth initiatives. This structure preserves founder involvement and institutional knowledge while delegating day-to-day operational leadership to an experienced external executive.
KMM specializes in complex, tight-tolerance precision components for the medical device industry, serving customers who require manufacturing capabilities that remain unavailable through conventional contract manufacturers. According to King's statement, KMM has built customer trust by solving complex manufacturing challenges, providing a differentiated market positioning. The capital infusion is expected to broaden this competitive moat by enabling capacity expansion and capability enhancement across the company's manufacturing footprint.
Transaction advisors included Middle Branch Partners, which represented KMM Group, and Choate, which provided legal counsel to RS2 Healthcare Partners.
The investment is accompanied by a leadership restructuring designed to balance growth acceleration with operational continuity. J. Mark King has been appointed President and Chief Executive Officer. King brings extensive industry credentials, including over 30 years in the medical device sector and prior service as President and CEO of Tegra Medical, a contract manufacturer that was itself a portfolio company of RS2 Healthcare Partners. His familiarity with RS2's operational framework and investment strategy positions him to execute growth initiatives while maintaining alignment with the private equity sponsor's value-creation thesis.
Co-founder John Shegda has assumed the role of Chief Technology Officer, with responsibility for engineering and technology strategy, while co-founder Eric Wilhelm has been named Executive Vice President of Business Transformation & Organizational Capability, overseeing operational excellence and scalable growth initiatives. This structure preserves founder involvement and institutional knowledge while delegating day-to-day operational leadership to an experienced external executive.
KMM specializes in complex, tight-tolerance precision components for the medical device industry, serving customers who require manufacturing capabilities that remain unavailable through conventional contract manufacturers. According to King's statement, KMM has built customer trust by solving complex manufacturing challenges, providing a differentiated market positioning. The capital infusion is expected to broaden this competitive moat by enabling capacity expansion and capability enhancement across the company's manufacturing footprint.
Transaction advisors included Middle Branch Partners, which represented KMM Group, and Choate, which provided legal counsel to RS2 Healthcare Partners.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.